EUVIMEDFaigh amach EUVIMED
Open access

Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway

Yangsheng Wu, Shijie Dai, YuJia Zhang, Zheming Li, Bo Zhu, Qingsheng Liu, Like Wo, Zhiling Yu, Xiaofeng Yuan, Xiaobing Dou

Journal of Cancer · 2024 · 15 (13) · 4328-4344

DOI: 10.7150/jca.96647 ↗

At a glance

Journal article in Journal of Cancer, 2024. Written by Yangsheng Wu and 9 co-authors. Institution: College of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Cited 13 times so far (Crossref). The full text is freely available in PubMed Central.

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

Purpose

Atractylodes macrocephala Koidz is a widely used classical traditional Chinese herbal medicine, that has shown remarkable efficacy in cancers. Colorectal cancer (CRC) is the most common malignant tumor globally. Interferon (IFN)-γ, a prominent cytokine involved in anti-tumor immunity that has cytostatic, pro-apoptotic, and immune-stimulatory properties for the detection and removal of transformed cells. Atractylenolides-II (AT-II) belongs to the lactone compound that is derived from Atractylodes macrocephala Koidz with anti-cancer activity. However, whether AT-II combined with IFN-γ modulates CRC progression and the underlying mechanisms remain unclear. The present study aimed to elucidate the efficacy and pharmaceutical mechanism of action of AT-II combined with IFN-γ synergistically against CRC by regulating the NF-kB p65/PD-L1 signaling pathway.

Methods

HT29 and HCT15 cells were treated with AT-II and IFN-γ alone or in combination and cell viability, migration, and invasion were then analyzed using Cell Counting Kit-8 (CCK-8) and Transwell assays, respectively. Furthermore, the underlying mechanism was investigated through western blot assay. The role of AT-II combined with IFN-γ on tumor growth and lung metastases was estimated in vivo. Finally, the population of lymphocytes in tumor tissues of lung metastatic C57BL/6 mice and the plasma cytokine levels were confirmed by flow cytometry and enzyme-linked immunosorbent assay (ELISA).

Results

AT-II or the combination IFN-γ significantly inhibited the growth and migration abilities of CRC cells in vitro and in vivo. The biological mechanisms behind the beneficial effects of AT-II combined with IFN-γ were also measured and inhibition of p38 MAPK, FAK, Wnt/β-catenin, Smad, and NF-kB p65/PD-L1 pathways was observed. Moreover, AT-II combined with IFN-γ significantly inhibited HCT15 xenograft tumor growth and lung metastases in C57BL/6 mice, which was accompanied by lymphocyte infiltration into the tumor tissues and inflammatory response inactivation.

Conclusions

The results showed that the AT-II in combination with IFN-γ could be used as a potential strategy for tumor immunotherapy in CRC. More importantly, the mechanism by which AT-II suppressed CRC progressions was by inhibiting the NF-kB p65/PD-L1 signal pathway.

Subjects

Author keywords

Atractylenolide IIColorectal cancerInterferon-γPD-L1.

Authors and institutions

  • College of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • College of pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Hangzhou Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.
  • The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
  • Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.

Cite

APA

Wu, Y., Dai, S., Zhang, Y., Li, Z., Zhu, B., Liu, Q., Wo, L., Yu, Z., Yuan, X., & Dou, X. (2024). Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway. Journal of Cancer, 15(13), 4328-4344. https://doi.org/10.7150/jca.96647

Vancouver

Wu Y, Dai S, Zhang Y, Li Z, Zhu B, Liu Q, et al. Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway. Journal of Cancer. 2024;15(13):4328-4344. doi:10.7150/jca.96647

BibTeX
@article{Wu2024,
  author = {Wu, Yangsheng and Dai, Shijie and Zhang, YuJia and Li, Zheming and Zhu, Bo and Liu, Qingsheng and Wo, Like and Yu, Zhiling and Yuan, Xiaofeng and Dou, Xiaobing},
  title = {Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway},
  journal = {Journal of Cancer},
  year = {2024},
  volume = {15},
  number = {13},
  pages = {4328--4344},
  doi = {10.7150/jca.96647}
}
Start for free →